NTRA250516P70000
- 0.60
- 0.000.00%
Natera Newsroom
Express News | Natera Shares Are Trading Lower. The Company Reported Results From Its DEFINE-HT Clinical Trial
Natera: Results Of DEFINE-HT Clinical Trial Shows Prospera Heart Is Predictive Of Clinical Outcomes And Outperforms Biopsy In Predicting Graft Dysfunction
Natera Announces That Its Ultra-Sensitive Signatera Genome Assay Is Now Broadly Available To Physicians In The United States.
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera Genome MRD Test
Natera To Present Data From 8 Studies at 2025 AACR Annual Meeting
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
Natera (NasdaqGS:NTRA) Climbs 11% in One Week
When Will Natera, Inc. (NASDAQ:NTRA) Turn A Profit?
Natera Is Maintained at Overweight by Barclays
Natera Analyst Ratings
Barclays Maintains Natera(NTRA.US) With Buy Rating, Cuts Target Price to $160
Natera Price Target Lowered to $160 From $200 at Barclays
Barclays Sticks to Their Buy Rating for Natera (NTRA)
RBC Capital Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $251
Market Sentiment Around Loss-Making Natera, Inc. (NASDAQ:NTRA)
Is the Market Bullish or Bearish on Natera?
RBC Capital Sticks to Its Buy Rating for Natera (NTRA)
Unusual Options Activity: NTNX, NTRA and Others Attract Market Bets, NTNX V/OI Ratio Reaches 133.3
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
Daily short sale tracking: Pfizer's short volume increased by 125 million, with a short sale ratio of 37%